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Abstract
Introduction: Microvesicles (MVs), earlier referred to as microparticles, represent a major type of extracellular vesicles
currently considered as novel biomarkers in various clinical settings such as autoimmune disorders. However, the analysis of
MVs in body fluids has not been fully standardized yet, and there are numerous pitfalls that hinder the correct assessment of
these structures.
Methods: In this study, we analyzed synovial fluid (SF) samples of patients with osteoarthritis (OA), rheumatoid arthritis (RA)
and juvenile idiopathic arthritis (JIA). To assess factors that may confound MV detection in joint diseases, we used electron
microscopy (EM), Nanoparticle Tracking Analysis (NTA) and mass spectrometry (MS). For flow cytometry, a method
commonly used for phenotyping and enumeration of MVs, we combined recent advances in the field, and used a novel
approach of differential detergent lysis for the exclusion of MV-mimicking non-vesicular signals.
Results: EM and NTA showed that substantial amounts of particles other than MVs were present in SF samples. Beyond
known MV-associated proteins, MS analysis also revealed abundant plasma- and immune complex-related proteins in MV
preparations. Applying improved flow cytometric analysis, we demonstrate for the first time that CD3+ and CD8+ T-cell
derived SF MVs are highly elevated in patients with RA compared to OA patients (p = 0.027 and p= 0.009, respectively, after
Bonferroni corrections). In JIA, we identified reduced numbers of B cell-derived MVs (p = 0.009, after Bonferroni correction).
Conclusions: Our results suggest that improved flow cytometric assessment of MVs facilitates the detection of previously
unrecognized disease-associated vesicular signatures.
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Introduction
The release of extracellular vesicles by various types of cells is
a ubiquitous process, and accompanies cellular activation and
apoptosis [1]. Among the various populations of extracellular
vesicles, microvesicles (MVs) (also referred to as microparticles in
the literature) appear to be particularly expedient in clinical
settings, as they are readily detectable by flow cytometry (FC) in
various biological fluids. These vesicles are in between , 80 and
400 nm in diameter [2,3] in biological fluids, and carry surface
molecules that are typical for the cell that releases them. High
number of studies suggest that MVs may serve as biomarkers in
several diseases including cardiovascular disorders, autoimmune
diseases and cancer [1]. However, there are numerous pitfalls that
may hinder the correct analysis of MVs especially in biological
samples. These include platelet activation in plasma samples
induced during collection and transportation of blood samples,
residual platelets in platelet-free plasma [4] or sample storage.
Furthermore, it has been shown that the isolation procedure itself
can have an impact on several parameters of vesicles, and might
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also induce artificial vesicle release from remaining intact cells or
platelets in the ‘platelet-free plasma’ [5]. All these issues may lead
to over- or underestimation of platelet-derived MV counts (for
a review see [1,6]). In addition, the presence of immune complexes
may also falsify the enumeration of MVs, particularly in diseases
associated with accelerated immune complex formation [2]. Novel
major improvements have facilitated standard analysis of MVs in
biological fluids [7,8] including improved FC settings and
preparation of platelet-free plasma. Recently we have developed
a simple method to discriminate between immune complexes and
MVs using low concentrations of a detergent by FC [2]. Here we
report the results of the first study in which we applied the
combination of several improved procedures and recommenda-
tions in the MV field for the analysis of synovial fluid (SF) samples.
Excessive formation of SF is a common clinical feature in
various arthritides including rheumatoid arthritis (RA), juvenile
idiopathic arthritis (JIA), and osteoarthritis (OA). Analysis of SFs in
these joint diseases may facilitate the establishment of early
diagnosis, and provide an insight into the pathomechanism.
Previous studies have shown that SF MVs were detectable by FC
[2], and of particular interest, CD41a+ vesicles have been shown to
be highly elevated in patients with RA compared to OA [9].
However, complex MV signatures have not yet been described.
Using standardized FC settings [7,8] and applying the novel
differential detergent lysis approach (in order to exclude the
abundant MV-mimicking non-vesicular events), this is the first
study to show various joint disease associated SF MV signatures.
Materials and Methods
Patients
Blood plasma was obtained from RA patients (9 women, 3 men,
mean age 6 s.d.: 60.5612.0 years; age range: 38–76 years) and
from patients with OA (6 women, 3 men, mean age 6 s.d.:
53.5612.79 years; age range: 31–67 years). SF samples from
patients with RA (7 women, 1 man, mean age 6 s.d.: 50.4618.5
years; age range 23–73 years, 2 patients were ACPA negative,
mean Disease Activity Score (DAS) score was: 5.69), OA (6
women; 2 men, mean age6 s.d.: 64.167.9 years; age range 50–71
years) and JIA (6 girls; 4 boys, mean age6 s.d.: 9.565.8 years; age
range 2–19 years) were included in this study. All RA patients
fulfilled the 2010 American College of Rheumatology/European
League Against Rheumatism classification criteria [10,11]. All JIA
patients showed oligoarticular manifestations. Patients with RA
and OA were treated in the Department of Rheumatology,
Semmelweis University (Budapest, Hungary), the National In-
stitute of Rheumatology and Physiotherapy (Budapest) and the
Department of Orthopedics, University of Szeged (Szeged,
Hungary). Patients with JIA were treated in the 2nd Department
of Pediatrics, Semmelweis University (Budapest). Plasma samples
drawn into citrate tubes were centrifuged twice at 2,500 g in order
to obtain platelet-free blood plasma. SF samples were centrifuged
once at 650 g for 20 minutes. Aliquots of the samples were stored
at 220uC until use. During the entire investigation period we
followed the guidelines and regulations of the Helsinki Declaration
in 1975, and the experiments were approved by the Hungarian
Scientific and Research Ethics Committee (TUKEB); all patients
signed an informed consent form. We obtained an informed
written consent from the parents of the children involved in our
study. The clinical and serological data of the patients were
documented at the time of venipuncture.
Isolation of Microvesicles
Cell-free SF samples were filtered through an 800 nm filter
(Millipore, Billerica, MA, USA) and MVs were pelleted at
20,500 g for 60 minutes in an Eppendorf 5417R centrifuge
(Hamburg, Germany), as described previously by many groups
[12–15]. After resuspending pellets were washed twice with
phosphate buffered saline (PBS) and MV preparations were
subjected to electron microscopy (EM), nanoparticle tracking
analysis (NTA) or mass spectrometry (MS).
Generation of Immune Complexes
Lactoferrin and anti-lactoferrin and ovalbumin-anti-ovalbumin
were mixed at 1:1 ratio, as described previously [2] (all reagents
from Sigma-Aldrich, St. Louis, MO, USA). We also isolated IgM
immune complexes from RA SF samples using anti-IgM agarose
column, as described previously [2]. Aggregates were analyzed by
NTA.
Electron Microscopy
To visualize MVs, pellets were fixed at RT for 60 minutes with
4% paraformaldehyde. After washing with PBS, the fixed pellets
were postfixed in 1% OsO4 (Taab, Aldermaston, UK) for 30
minutes, dehydrated in graded ethanol, block stained with 1%
uranyl-acetate in 50% ethanol for 30 minutes, and embedded in
Taab 812 (Taab). The ultrathin sections were analyzed with
a Hitachi 7100 electron microscope (Hitachi, San Jose, CA, USA).
Nanoparticle Tracking Analysis
For particle size determination, nanoparticle tracking analysis
(NTA) was performed with a NanoSight LM10 instrument
(NanoSight Ltd., Amesbury, UK) as described previously [16].
NTA captures real-time video files, showing particles moving by
Brownian motion. A sample video file recorded by NTA is
available in the Supporting Material (Video S1). A 635 nm laser is
used to illuminate nanoparticles in liquid suspension between
concentrations of 106 and 109 particles per ml. The light scattered
from the particles allows them to be visualized using a long
working distance620 microscope objective fitted to an otherwise
conventional microscope. Attached to this microscope is an
EMCCD camera running at 30 frames a second which allows
a video of the particles moving under Brownian motion to be
obtained. The speed of moving particles is determined on
a particle-by-particle basis, and the size is calculated using the
Stokes-Einstein equation [16]. The concentration of particles is
determined directly from the chamber volume and particle
number. Immune complexes, native SFs, diluted 1:1,000 to
1:10,000 in filtered PBS (depending on particle concentration) as
well as isolated MVs were also analyzed using this method. A
video of 60 seconds duration was recorded, and data analysis was
carried out using the NTA 2.1 analytical software (NanoSight
Ltd.).
Mass Spectrometry
Isolated MVs (see above) were submitted to repeated freeze–
thaw cycles and the protein content of the vesicles was digested as
reported previously [17]. The LC–MS/(MS) analysis of the tryptic
peptide mixtures was performed using a nanoflow ultra perfor-
mance liquid chromatography system (nanoAcquity UPLC,
Waters, Milford, MA, USA) coupled to a Q-TOF Premier mass
spectrometer (Waters). All MS/MS samples were analyzed using
Mascot (Matrix Science, London, UK; version Mascot 2.2) and X!
Tandem (The GPM, thegpm.org; version 2007.01.01.1). X!
Tandem was searched against SwissProt_51.6 database assuming
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trypsin. Mascot was searched against SwissProt_51.6 database
assuming digestion enzyme trypsin. One missed cleavage was
allowed. Mascot and X! Tandem were searched with a fragment
ion mass tolerance of 0.15 Da and a parent ion tolerance of
50 ppm. Iodoacetamide derivative of cysteine was specified in
Mascot and X! Tandem as a fixed modification. Scaffold (version
Scaffold_3_00_07, Proteome Software Inc., Portland, OR, USA)
was used to validate MS/MS based peptide and protein
identifications. Peptide identifications were accepted when they
could be established at greater than 95.0% probability as specified
by the Peptide Prophet algorithm [18]. Protein identifications were
accepted when they could be established at greater than 99.0%
probability and contained at least 2 identified peptides. Protein
probabilities were assigned by the Protein Prophet algorithm [19].
Proteins that contained similar peptides and could not be
differentiated based on MS/MS analysis alone were grouped to
satisfy the principles of parsimony. Search against the decoy
database gave a false-discovery rate of 0.51% when using p,0.01
significance level. Presented results show summarized data from
three independent biological replicates, respectively. In case of one
sample three technical replicate experiments were also carried out
and the results were also taken into consideration.
Flow Cytometry
Samples were analyzed using a FACSCalibur flow cytometer
(BD Biosciences, Franklin Lakes, NJ, USA). The FC instrument
settings and MP gating were adopted from previous works
[2,9,20]. We used a 1 mm bead (Sigma-Aldrich) to determine
the upper right corner of the gate [7], (Figure S1a). The lower
border was determined after assessing signal/noise ratios and
positive event numbers, as described previously [2]. To identify
and characterize MVs, annexin V-(AX) fluorescein isothiocyanate,
anti-CD3-phycoerythrin, anti-CD4-phycoerythrin, anti-CD8-phy-
coerythrin, anti-CD14-peridinin chlorophyll protein, anti-CD19-
peridinin chlorophyll protein, anti-CD41a-fluorescein isothiocya-
nate, anti-receptor activator of nuclear factor kappa B (RANK)-
phycoerythrin and anti-RANK ligand (RANKL)-phycoerythrin
were used (all from BD Biosciences) (Figure S1b). We applied our
earlier protocol for staining MVs in biological fluids, with some
modifications [2,21]. Briefly, 1 mg of antibodies was added to
20 ml of plasma/SF, and incubated for 30 minutes at RT. To
reduce the numbers of background events, samples were diluted to
400 ml in 0.01 mm pore size membrane-filtered PBS (Millipore). In
the case of AX staining, we added 2 ml of AX-fluorescein
isothiocyanate to the samples diluted 1:20 in annexin-binding
buffer (BD Biosciences). Event numbers of equal sample volumes
were counted for 60 seconds. Background fluorescence was
compared with that of the isotype-control antibodies. When
detecting AX binding, 5 mM ethylenediaminetetraacetic acid-
containing annexin-binding buffer solution was used to determine
the background fluorescence. To determine the exact MV
concentrations, we used fluorescent counting beads (3 mm in
diameter, Partec GmbH, Mu¨nster, Germany). We enumerated the
counting beads on the SSC/FL-2 plot (Figure S1c). To determine
MV concentrations, we used the following equation: ‘MV count/
ml = (MV event count/bead event count)6bead concentration6
plasma dilution’.
To exclude protein aggregates and immune complex-related
events, we applied the method of differential detergent lysis.
Differential Detergent Lysis
In order to discriminate between MVs and protein aggregates,
we benefited from our previous observations that vesicular
structures were more susceptible to detergent lysis compared to
immune complexes and protein aggregates [2]. By FC, we applied
0.1% of Triton X-100, a concentration which had been
determined in preliminary measurements. Events resistant to this
concentration were excluded from MV counts, therefore event
count after Triton X-100 lysis was subtracted the from event
number before lysis. Remaining event counts were referred to
known concentration of fluorescent counting beads. The effect of
the differential detergent lysis was also confirmed using a BD
LSRII flow cytometer (BD Biosciences).
Statistical Analysis
SPSS software Version 15.0 was used for statistical analyses. We
used Kruskal-Wallis nonparametric test to analyze data of RA,
OA and JIA groups. As a post-hoc test, we compared individual
groups using the Mann-Whitney test, and we used Bonferroni
correction for multiple statistical testing. Correlations between
clinical and serologic data were analyzed using Spearman or
Pearson correlation.
Results
Analysis of the MV Pellet by EM and NTA
EM images of SF-derived MV preparations (20,500 g pellets)
clearly showed vesicular structures of 80–400 nm in diameter in all
tested SFs (n = 3 in each patient group) (Figure 1a). This size range
was consistent with our previous findings [2]. Strikingly, significant
amounts of amorphous substance were also present among the
vesicles in all EM preparations, in spite of the fact that the pellets
were washed twice. MV preparations from RA and OA SFs were
subsequently analyzed by NTA, and light scattering of particles
was recorded (an example is shown in Video S1). Based on the
NTA video files, we determined distributions of particle size in the
20,500 g pellets of RA and OA SF preparations (Figure 1b and
1c). A peak in the MV diameter range (determined by EM, see
above) was detectable at around 150–200 nm (Figure 1c).
However, strikingly, a significant portion of particles did not fall
into the size range of MVs: in the case of OA and RA samples,
60.5% 612.5% and 50.4% 66.0% of the particles fell below
80 nm in diameter, respectively. These events are likely to be non-
vesicular structures, as MVs smaller than 80 nm were not detected
in the EM preparations from the same samples. The application of
0.1% TritonX-100 resulted in the reduction in the particle
concentration between 100 and 200 nm and increased the
concentration of particles below 100 nm (Figure S2). Next, we
analyzed if pure immune complexes and protein aggregates
formed particles, detectable by NTA. The size histograms of
artificial immune complexes (lactoferrin-anti-lactoferrin, ovalbu-
min-anti-ovalbumin, isolated IgM immune complexes) and protein
aggregates (in BSA solution) partly overlapped the MV size range,
but most of the events were smaller than 100 nm in diameter
(Figure S3). Taken together these data, these results suggest that
particles other than MVs (protein aggregates, immune complexes)
are also present in relatively high numbers in the 20,500 g SF
pellets.
MS Analysis of MV Pellets
To further analyze the nature of non MV-related events found
in MV preparations of OA, RA and JIA SFs, we performed MS
analysis of the 20,500 g pellets (n = 3 in each group). Total protein
concentrations in RA pellets (mean 6 s.d: 0.8860.63 mg/ml) and
JIA pellets (mean 6 s.d: 0.5160.48 mg/ml) were higher
compared to OA samples (mean 6 s.d: 0.1460.10 mg/ml) (not
significant). We identified 105, 98 and 88 proteins in OA, RA and
in JIA pellets, respectively (Table S1). Among the identified
Improved Assessment of Microvesicles
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proteins, known MV-associated proteins were clearly detectable in
all the samples. These included cytoskeletal components (actin,
actin-binding proteins (profilin-1, cofilin-1), myosin, tubulin),
enzymes (alpha-enolase, pyruvate kinase, triosephosphate isomer-
ase), membrane molecules (HLA-I, HLA-II antigens, Na/K ATP-
ase) and proteins involved in vesicle biogenesis and trafficking (e.g.
Ras-related proteins). The presence of lactadherin that binds to
the phosphatidyl-serine surface of MVs [22], also confirms the
presence of MVs in the pellets. We also detected clusterin (ApoJ) in
all patient groups, a protein involved in the clearance of apoptotic
bodies and cell debris [23]. Besides canonical MV proteins,
numerous plasma proteins (e.g. albumin, transferrin, fibrinogen,
prothrombin, haptoglobin) and immune-complex related proteins
(complement proteins and immunoglobulins) were also identified
by MS. These results further support the hypothesis that MV
pellets (prepared by conventional differential centrifugation),
contain high numbers of plasma proteins and immune-complex
related proteins as non-vesicular contaminants. Most interestingly,
the identified protein patterns were almost identical in all samples
irrespectively of the type of the joint disease (OA, RA or JIA)
(Table S1).
Flow Cytometric Analysis of Samples
Routine diagnostic assessment of MVs comprises the analysis of
diluted biological samples. Previously we have shown that the
presence of immune complexes may falsify the estimation of MV
counts [2]. Using differential detergent lysis, we could identify
MVs in SF samples (Figure 2a) based on both surface staining and
detergent sensitivity. With this approach, immune complex
particles were also detected in JIA SF samples (Figure 2b),
similarly to what had been shown previously in the case of RA [2].
Interestingly, in the case of certain cell surface labeling, positive
event counts were not reduced after detergent lysis. A striking
example is shown in Figure S4a where CD68 staining of MVs was
carried out by a standard BD antibody. Events within the MV gate
did not disappear after the addition of detergent and were also
present in PBS and in BSA solutions (Figure S4b). These MV
mimicking, anti CD68 fluorescence signals became stronger with
increasing concentration of BSA (Figure S4c). As all biological
samples have different protein concentrations, aggregation of
CD68 antibodies may also be different leading to false conclusions,
if detergent lysis is not used.
Figure 1. Analysis of SF MVs by EM and NTA. (a). Electron micrographs of the 20,500 g pellets from SFs are shown. Scale bars denote 500 nm,
original magnification was 30,0006. (b). NTA screenshot from an RA SF pellet, showing light scattering particles. The field of view is 120 mm by
80 mm. (c). Size histograms of particles in SFs obtained by NTA measurements. A small peak is visible in the MV size range indicated by an arrow
(between 100 and 200 nm), however, most particles are below 100 nm in diameter.
doi:10.1371/journal.pone.0049726.g001
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Immunophenotyping of MVs by FC
Using differential detergent lysis and counting beads, we
phenotyped and counted MVs in RA (n = 8), OA (n = 8) and
JIA SF samples (n = 10) (Figure 3). AX+ MV counts in SF were
slightly, however, not significantly elevated in RA (range:1.06107–
6.56107/ml) and in JIA patients (range: 4.56106–1.46108/ml)
compared to OA (range: 6.86106–1.06108/ml) consistent with
our previous findings [2] (Figure 3). Most vesicles were derived
from B-cells and T-cells in the case of OA and RA SF samples.
Monocyte- and platelet MVs were present in lower amounts in
SFs. Synovial CD41a+ vesicles were elevated in RA compared to
OA and JIA patients, in concordance with previous findings [9],
however, this elevation was not significant. Most interestingly,
CD3+ T-cell derived vesicles were highly elevated in patients with
RA compared to OA (p = 0.027, Mann-Whitney test, Bonferroni
correction) in our study.
Next, we tested T-cell subset-derived MVs in SFs. Both CD4+
and CD8+ vesicles were present in the samples, however, only
CD8+ MVs showed significant elevation in RA compared to OA
(p = 0.009, Mann-Whitney test, Bonferroni correction). Interest-
ingly, B-cell-derived vesicle counts were significantly lower in JIA
compared to OA and RA samples (p = 0.009 and p = 0.004,
respectively, for B-cells, Mann-Whitney test, after correction).
Counts of CD8+ and CD3+ events showed correlation in the
samples (R = 0.525, p = 0.007, Spearman correlation). To assess
whether CD3+ and CD8+ counts of vesicles were elevated not only
locally but also systematically in RA patients, we analyzed RA and
OA plasma samples. CD3+ and CD8+ vesicle counts were
undetectable in the blood plasma in both groups, indicating the
local production of these MVs (p,0.001, Mann-Whitney test)
(data not shown).
Given that the tested joint diseases are known to be
accompanied by bone erosions, we also tested whether the RANK
and RANK-ligand were associated with MVs. Interestingly, we
could detect vesicles carrying these surface molecules in all groups,
however, very few MVs were stained (Figure 3). The highest
numbers were detected in RA; however, the differences among
disease groups were not significant.
Associations with Clinical Parameters
Finally we tested whether the number of MVs correlated with
either the clinical or the serological data of patients. Interestingly,
the level of rheumatoid factor (RF) showed robust correlations
with both T-cell- and B-cell-derived MV numbers in RA (Pearson
correlation, R = 0.912, p = 0.002 and R = 0.956, p = 0.001, re-
spectively). T- and B-cell-derived MV counts also showed strong
correlation with one another (p,0.001, R = 0.876). DAS Score,
Visual Analogue Scale score and anti-citrullinated protein
antibody levels did not correlate with MV counts. However,
disease duration positively correlated with the CD41a+ MV counts
(Pearson correlation, R = 0.886, p = 0.008). SF cell number
showed only a weak correlation with CD3+ and CD8+ MV counts
(Pearson correlation, R = 0.883, p = 0.039 and R = 0.892,
p = 0.017), and showed no correlation with other MV phenotypes,
suggesting that the count of MVs reflect the state of cellular
activation rather than the number of the cells.
Discussion
In the past few years, the number of publications assessing MVs
by flow cytometry platforms has risen rapidly. However, pitfalls of
MV measurement have also received increasing attention in the
past few years. Efforts to standardize sample collection and FC
measurements have already led to numerous results; however, the
standardization work is still in progress [7,8]. In our present study
we aimed at benefiting from recent developments in this field in
order to reveal novel disease-associated MV signatures. These
developments included i) the use of standard preanalytical
conditions, ii) bead-based definition of MV gates, iii) bead-based
MV enumeration, and iv) discrimination of MVs from non-
vesicular structures.
Biological fluids contain high amounts of proteins, which may
form aggregates or complexes under certain circumstances. We
have shown earlier that protein aggregates share biophysical
Figure 2. Differential detergent lysis by FC. Events are shown within the MV gate. Background fluorescence was determined using an isotype
control antibodies. Values show percents of positive events. Counting beads are visible in the upper right corner of the dot plots. (a). CD3+ and CD8+
vesicles were detected by FC. Most positive events disappear after the addition of 0.1% Triton X-100. Remaining events were subtracted from the
original event counts. (b). Detergent-resistant IgG and IgM staining in JIA SF samples suggested that these events were related to immune complexes
rather than vesicular structures.
doi:10.1371/journal.pone.0049726.g002
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parameters with MVs that may confound correct assessment of
these structures [2]. Using EM and NTA, here we demonstrated
the presence and abundance of particles other than vesicular
structures in MV pellets. These non-vesicular structures may
correspond to immune-complexes, protein aggregates [2] or
membrane fragments formed during centrifugation. In addition,
they might derive from lysed, disrupted MVs [5]. Centrifugation
alone is not sufficient to pellet out all cells, for instance even after
a 2,880 g 20 minutes and a subsequent 10,840 g 5 minutes
centrifugation, platelets have been shown to be still present in the
‘platelet-free plasma’ (up to a concentration of 47/ml, which
corresponded to 0.02% of the original platelet count) [4]. The
high-speed centrifugation of cells during MV isolation results in
high shear stress that may tear off membrane fragments or even
vesicles from these remaining cells [5]. However, fragmentation of
cells during the 20,500 g centrifugation probably did not
contribute to the amorphous structures seen by EM in our study,
because we used a gentle, gravity driven filtration of the SFs
through an 800 nm membrane prior to centrifugation. To our
surprise, using NTA we detected predominantly very small sized
particles in 20,500 g pellets. EM analyses of numerous samples,
however, ruled out the possibility that small size (,80 nm) vesicles
Figure 3. Immunophenotyping of SF MVs by FC. MV count/ml is shown in the y axis. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0049726.g003
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(easily recognized based on membrane osmium staining) were
present in these preparations. Therefore, the abundant light
scattering small ‘particles’ in NTA were more likely protein
aggregates rather than vesicles. MS analysis in this work also
demonstrated the presence of primarily non-MV related proteins.
Although it can not be excluded that SF MVs can harbor certain
plasma proteins, the presence and abundance of nearly all major
plasma- and immune complex-related proteins in the MV
preparations makes it unlikely that all these proteins were
associated with vesicles.
Improved MV measurement by FC should exclude these non-
MV related events. For discrimination, we suggested the use of
differential detergent lysis method. In this paper we provided an
example how omission of this step may lead to false conclusions,
even when using standard, controlled antibodies.
Interestingly, total particle counts, measured by NTA, were two
orders of magnitude higher than the total (AX+) counts detected by
FC. This supports the ‘iceberg’ theory which assumes that FC only
detects particles above 200–300 nm (although the detection
threshold is also dependent on the refractive index of the particles,
[24]) and most of the particles in SFs fall below this range. On the
other hand, NTA detects any particles, whereas by FC we
enumerated only the true (AX-positive, Triton sensitive) vesicle-
related events. However, using the fluorescence capability of the
NTA system and specific labeling, individual populations may also
be analyzed in the future [16].
After using the differential detergent lysis approach to evaluate
MV signatures in SFs, we observed for the first time that CD3+
and CD8+ MVs were highly elevated in patients with RA
compared to OA.
T-cells, in particular CD4+ cells have been implicated in the
pathogenesis of RA as summarized by a recent review [25]. In
spite of numerous observations that suggested a role of CD8+ T
cells in RA, CD8+ T cell involvement is absent from the current
mainstream understanding of the pathomechanism of RA.
Evidence for the role of CD8+ T cells includes that CD8+ T
cells were present in high numbers in the SFs of RA patients
[26,27]. Moreover, phenotype analysis of SF T-cells confirmed
that the accumulating T-cell clones in RA were predominantly
CD8+ memory T cells [26]. Furthermore, memory CD8+ T-cells
in RA were found to be specific to viruses, such as Epstein-Barr
virus, cytomegalovirus or influenza virus [28]. It has also been
suggested that CD8+ cells may contribute to the pathogenesis of
RA by regulating structural integrity and functional activity of
germinal centers in the synovium [29]. The MV signatures that we
detected in this study may reflect either elevated SF CD8+ T cell
numbers or CD8+ T cell activation in the RA joints. The latter
may have importance, since CD8+ and CD4+ T cell counts were
found to be similar in both RA and OA [30]. Thus, our data might
reflect a locally enhanced activation of the CD8+ T cell
population. As part of the SF MV signature of RA, here we also
found an elevated number of platelet-derived in RA SFs in
accordance with the findings of Boilard et al [9]. Similarly, the
number of both RANK and RANKL positive MVs was found to
be elevated in RA SFs.
Even though JIA is an inflammatory disease characterized by
the proliferation of B-cells, in this study we detected a strikingly
reduced number of B-cell-derived MVs in SFs of patients with JIA.
This was possibly due to the fact that we analyzed only JIA
patients with oligoarticular involvement. As shown in a recent
report, synovial CD20 expression differs significantly between
polyarticular and oligoarticular JIA patient groups [31]. Patients
with polyarticular involvement have three times higher expression
of CD20 in the synovium. Our present study suggests that
oligoarticular JIA may have distinct MV signature from other joint
diseases.
In conclusion, our data suggest that the differential detergent
lysis method and other improvements in MV assessment by FC
may provide important novel insights into the pathomechanism of
RA and other joint diseases.
Supporting Information
Figure S1 MV gate (R1) was determined using a 1 mm
calibration bead (arrow) (a) Arrowhead shows counting beads
(3 mm in diameter). MVs were stained with AX, events are shown
from the MV gate (b). The background was determined adding
5 mM EDTA to the samples. The number of counting beads was
determined on the SSC/FL-2 dot plot (R2 gate) (c).
(TIF)
Figure S2 Size histograms of particles in an MV preparation
from an RA patient, obtained by NTA. Dashed line represents
0.1% TritonX-100 treated sample.
(TIF)
Figure S3 Size histograms of immune complexes and protein
aggregates measured by NTA. Lactoferrin (LF) was mixed 1:1 with
anti-lactoferrin, ovalbumin (OVA) was mixed 1:1 with anti-
ovalbumin. IgM immune complexes were isolated from RA SF
using anti-IgM agarose column.
(TIF)
Figure S4 Flow cytometric MV-mimicking signals using an anti-
CD68 antibody. The fluorescent events do not disappear after
detergent lysis in blood plasma (a) and in BSA solution (b). The
increasing concentration of BSA results in stronger fluorescent
signals. The y axis represents event number/ml (c).
(TIF)
Table S1 MS analysis of MV preparations from patients with
RA, OA and JIA.
(XLS)
Video S1 Sample NTA screenshot of an MV preparation from
an RA patient. The field of view is 120 mm by 80 mm.
(WMV)
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